Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04072458 · ClinicalTrials.gov registry record · Phase 1
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
A Phase 1 study of Mantle Cell Lymphoma and Follicular Lymphoma, sponsored by Bio-Path Holdings.
- Active
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 5
- Study locations
NCT04072458: Active Phase 1 study of Mantle Cell Lymphoma and Follicular Lymphoma, sponsored by Bio-Path Holdings.
NCT04072458 is a Phase 1 study of Mantle Cell Lymphoma and Follicular Lymphoma that is active but no longer recruiting, run by Bio-Path Holdings. The registered enrollment target is 30 participants, below the 104-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (71% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04072458, a Phase 1 study of Mantle Cell Lymphoma and Follicular Lymphoma, is active but no longer recruiting, sponsored by Bio-Path Holdings.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study evaluates the safety, pharmacokinetics, and efficacy of BP1002 (L-Bcl-2) antisense oligonucleotide in patients with advanced lymphoid malignancies. Up to 12 evaluable patients with a diagnosis of relapsed or refractory lymphoid malignancies are expected to participate.
Primary Outcome
Identify DLT of BP1002 using non-hematologic and hematologic measures per NCI CTCAE criteria
Conditions Studied
Interventions
- DRUG L-Bcl-2 antisense oligonucleotide
Study Locations (5)
Texas
- University of Texas Southwestern Medical Center - Dallas
- MD Anderson Cancer Research Center - Houston
Georgia
- Georgia Cancer Center - Augusta
New York
- New York Medical College / Westchester Medical Center - Valhalla
Tennessee
- Sarah Cannon Research Institute/Tennesee Oncology - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-11-05 |
| Est. Completion | 2025-04 |
| Phase | Phase 1 |
What the registry record for NCT04072458 still lists
NCT04072458 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 104-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (71% lower).
The record links to 10 conditions, with Mantle Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which L-Bcl-2 antisense oligonucleotide is the first listed.
NCT04072458 lists 5 locations in 4 states (Texas, Georgia, New York).
Frequently Asked Questions
What is clinical trial NCT04072458 about?
NCT04072458 is a clinical study titled "A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies". This study evaluates the safety, pharmacokinetics, and efficacy of BP1002 (L-Bcl-2) antisense oligonucleotide in patients with advanced lymphoid malignancies. Up to 12 evaluable patients with a diagnosis of relapsed or refractory lymphoid malignancies are expected to participate.
What is the current status of trial NCT04072458?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2020-11-05. Estimated completion is 2025-04.
What conditions does trial NCT04072458 study?
This clinical trial studies the following conditions: Mantle Cell Lymphoma, Follicular Lymphoma, Hodgkin Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia.
What interventions are being tested in trial NCT04072458?
The interventions under investigation include: L-Bcl-2 antisense oligonucleotide (DRUG).
Who is sponsoring clinical trial NCT04072458?
This trial is sponsored by Bio-Path Holdings, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04072458 being conducted?
This trial has 5 study locations across Georgia, New York, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mantle Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04072458's enrollment target sits among peer trials
30 65th of 102 higher than 35 of 102 other Mantle Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mantle Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
RECRUITING · Phase 1
-
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RECRUITING · Phase 1
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI